Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma. 2017

Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
National Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Sciences and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Oral mucosal malignant melanoma (OMM) is extremely rare and has a poor prognosis. Owing to its rarity, it has not yet been possible to establish an optimal treatment modality. The objective of this study was to evaluate the long-term efficacy of carbon-ion radiotherapy (C-ion RT) for OMM. Between 1997 and 2013, 19 patients with OMM were treated with C-ion RT alone. Patient ages ranged from 44 to 84 years (median, 69 years). Nine men and 10 women were included. OMMs were restaged in accordance with the seventh edition of the tumour/node/metastasis (TNM) Staging System of the International Union Against Cancer. Before treatment, 14 patients had T3 disease and 5 had T4a disease. Three patients were classified as having N1 disease. All patients were classified as having M0. The hard palate was the most frequently involved oral subsite. All patients were treated with 57.6 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 61 months (range, 8-190 months). The 5-year local control, overall survival and progression-free survival rates were 89.5%, 57.4% and 51.6%, respectively. For local control and overall survival, T classification was found to be a significant prognostic factor. Grade 2 and 3 osteoradionecrosis was observed in three and four patients, respectively. The presence of teeth within the planning target volume was a significant risk factor for developing osteoradionecrosis. C-ion RT was an effective treatment option with acceptable toxicity for OMM.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009061 Mouth Mucosa Lining of the ORAL CAVITY, including mucosa on the GUMS; the PALATE; the LIP; the CHEEK; floor of the mouth; and other structures. The mucosa is generally a nonkeratinized stratified squamous EPITHELIUM covering muscle, bone, or glands but can show varying degree of keratinization at specific locations. Buccal Mucosa,Oral Mucosa,Mucosa, Mouth,Mucosa, Oral
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
April 2019, Cancers,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
October 2016, Journal of medical case reports,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
September 2018, Cancer science,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
May 2009, International journal of radiation oncology, biology, physics,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
September 2021, Cancer science,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
January 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
January 2020, Head & neck,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
April 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.],
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
January 2007, Japanese journal of ophthalmology,
Kensuke Naganawa, and Masashi Koto, and Ryo Takagi, and Azusa Hasegawa, and Hiroaki Ikawa, and Kazuo Shimozato, and Tadashi Kamada, and Yoshitaka Okamoto, and
December 2019, Cancer medicine,
Copied contents to your clipboard!